Statistics

Total Visits

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab43

Select a period of time:

Number of views in the range

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab26

Views

Views
October 20240
November 20241
December 20241
January 20252
February 20255
March 202517
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States10
Germany1
 

Top cities views

Views